ANIP - Why Investors Have Severely Underestimated ANI Pharmaceuticals' And Its Cortrophin SNDA
Company Thesis
ANI Pharmaceuticals' (ANIP) cortrophin will likely be the sole generic competitor to Mallinckrodt's (MNK) blockbuster H.P. Acthar Gel, besting Assertio Therapeutics' (ASRT) investigative cosyntrophin by a wide margin. The company's 5 key branded launches in the past fiscal year have the potential to add $50-200 million in peak sales. Consistent organic growth led by ANIP's management is likely to offset sector headwinds and steer the company clear of implied opioid liabilities. All combined with one of the lowest leverage ratios in the specialty-generic sector, this makes